摘要
目的探讨阿托伐他汀联合通心络胶囊治疗冠心病（coronary heart disease，CHD）的临床疗效及安全性。方法分析我院自2011年4月～2013年1月收治的冠心病患者113例，按照随机数字表法分成观察组58例和对照组55例。观察组给予阿托伐他汀和通心络联合治疗，对照组单独给予阿托伐他汀。两组均以3个月为一个疗程，比较治疗后两组临床疗效、血清总胆固醇（TC），血清甘油三酯（TG）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）及不良反应情况。结果①对照组与观察组临床总有效率分别为63．6％（35／55）、81．0％（47／58）（x2=4．29，P〈0．05）。②对照组与观察组治疗后比较，在TC、TG,LDL—C水平比较，差异有统计学意义（P〈0．05），HDL—C水平比较，差异无统计学意义（P〉0．05）。③对照组与观察组胃肠道不良反应发生率5．4％（3／55）及8．6％（5／58）（X2=0．43，P〉0．05）。结论阿托伐他汀与通心络胶囊联合治疗CHD疗效确切，有效降低血脂水平，且安全性较好。
Objective To explore the safety and curative effect of Atorvastatin and Tongxinluo capsule in the treatment of coronary heart disease（CHD）. Methods A total of 113 CHD cases from April 2011 to January 2013 were randomly divided into observation group （58 cases）and control group （55 cases）. Observation group was given atorvastatin and Tongxinluo and the control group was given atorvastatin. Two groups were treated for one period of 3 months. Clinical curative effect,serum total cholesterol（TC）, serum triglyceride （TG）, low density lipoprotein （LDL-C）, high density lipoprotein （HDL-C） and adverse reactions were compared. Results （1）The clinical total effective rate of control group and observation group were 63.6%（35/55） and 81.0%（47/58） （X2--4.29, P 〈 0.05）. （2）The level of TC, TG, LDL-C comparison （P 〈 0.05）, HDL-C level（P 〉 0.05） in two groups after treatment. （3）The incidence of gastroin-testinal adverse reaction were 5.4% （3/55） and 8.6% （5/58） （X2=0.43, P 〉 0.43）. Conclusion Atorvastatin and Tongxinluo capsules in the treatment of CHD have curative effect and better security, can reduce blood lipid levels effectively.
出处
《中国现代医生》
2013年第20期50-51,共2页
China Modern Doctor
关键词
冠心病
阿托伐他汀
通心络胶囊
安全性
疗效
Coronary heart disease
Atorvastatin
Tongxinluo capsule
Security
Effect
